Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.14694/EdBook_AM.2014.34.e497 http://scihub22266oqcxt.onion/10.14694/EdBook_AM.2014.34.e497 C4892842!4892842!24857145     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24857145&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24857145.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Am+Soc+Clin+Oncol+Educ+Book 2014 ; ä (ä): e497-502 Nephropedia Template TP {{tp|p=24857145|t=2014. Taking on Challenging Targets: Making MYC Druggable |pdf=|usr=}}{{24857145}} gab.com Text Taking on Challenging Targets: Making MYC Druggable JO: Am Soc Clin Oncol Educ Book http://www.kidney.de/pget.php?&tw=1&pmid=24857145 #FOAvip The transcription factor proto-oncogene c-MYC (hereafter MYC) was first identified more than three decades ago, and has since been found deregulated in a wide variety of the most aggressive human malignancies. As a pleiotropic transcription factor, MYC directly or indirectly controls expression of hundreds of coding as well as non-coding genes, which affect cell cycle entry, proliferation, differentiation, metabolism, and death / survival decisions of normal and cancer cells. Tumors with elevated MYC expression often exhibit highly proliferative, aggressive phenotypes and elevated MYC expression has been correlated with diminished disease-free survival for a variety of human cancers. The use of MYC overexpression or MYC-dependent transcriptional gene signatures as clinical biomarkers is currently being investigated. Furthermore, pre-clinical animal and cell-based model systems have been extensively utilized in an effort to uncover the mechanisms of MYC-dependent tumorigenesis and tumor maintenance. Despite our ever-growing understanding of MYC biology, currently no targeted therapeutic strategy is clinically available to treat tumors that have acquired elevated MYC expression. Here we summarize the progresses being made to discover and implement new therapies to kill MYC over-expressing tumors, a target that was once deemed undruggable. Twit Text FOAVip Taking on Challenging Targets: Making MYC Druggable ????Am Soc Clin Oncol Educ Book http://www.kidney.de/pget.php?&tw=1&pmid=24857145 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24857145 #FOAvip English Wikipedia <ref>{{Cite pmid|24857145}}</ref> Taking on Challenging Targets: Making MYC Druggable #MMPMID24857145 Horiuchi D; Anderton B; Goga A Am Soc Clin Oncol Educ Book 2014[]; ä (ä): e497-502 PMID24857145show ga The transcription factor proto-oncogene c-MYC (hereafter MYC) was first identified more than three decades ago, and has since been found deregulated in a wide variety of the most aggressive human malignancies. As a pleiotropic transcription factor, MYC directly or indirectly controls expression of hundreds of coding as well as non-coding genes, which affect cell cycle entry, proliferation, differentiation, metabolism, and death / survival decisions of normal and cancer cells. Tumors with elevated MYC expression often exhibit highly proliferative, aggressive phenotypes and elevated MYC expression has been correlated with diminished disease-free survival for a variety of human cancers. The use of MYC overexpression or MYC-dependent transcriptional gene signatures as clinical biomarkers is currently being investigated. Furthermore, pre-clinical animal and cell-based model systems have been extensively utilized in an effort to uncover the mechanisms of MYC-dependent tumorigenesis and tumor maintenance. Despite our ever-growing understanding of MYC biology, currently no targeted therapeutic strategy is clinically available to treat tumors that have acquired elevated MYC expression. Here we summarize the progresses being made to discover and implement new therapies to kill MYC over-expressing tumors, a target that was once deemed undruggable. äTaking on Challenging Targets: Making MYC Druggable (epmc).pdf DeepDyve Pubget Overpricing